PATENT CLAIM ANALYSIS

Application Number: 15863667
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["536", "024500"]

Abstract:
A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

Claim (Index 58):
The oligonucleotide according to  claim 48 , wherein the remaining nucleosides of regions A and C are alpha-D-oxy-LNA nucleosides.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 86.0
- Lexical Diversity: 1.28889
- Patent Class: 536.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15619134', '15618892', '13797913', '15237307', '10535472']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8174827238351038
- 35 USC 102 Novelty (BERT): 0.6427805328370063
- Combined Prediction Score: 0.8000125047352941
- Mean Citation Score: 714.734328
- Max Citation Score: 738.5011
- Similarity Product: 556.5172188705742

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test